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Huntington’s disease (Huntington’s chorea) is an autoso-
mal dominant disease of the human brain caused by an
unstable expansion of CAG trinucleotide triplet repeats
in the huntingtin gene at 4p16.3; the CAG repeats are
transcribed and translated into polyglutamine expansion
(polyQ) stretches, and the length of the repeats corre-
lates inversely with age of onset. Huntington’s disease is
characterized by motor dysfunction, with chorea and
incoordination occurring relatively early and dystonia,
rigidity and bradykinesia becoming more prominent
with time; death usually occurs within 15-25 years of
onset of motor symptomatology. The key neuropatholo-
gical change is neuronal degeneration, particularly in the
striatum. The scientific background is given for why
fatty acids may play an important role in Huntington’s
disease. Evidence is then presented from a randomized
double-blind placebo-controlled to show that ultra-pure
ethyl-eicosapentaenoic acid (ethyl-EPA), a semi-
synthetic, ethyl ester of eicosapentaenoic acid, is asso-
ciated with clinical improvement in motor functioning
in Huntington’s disease. The likely mechanisms of this
beneficial action are then described. Finally, the results
are detailed of a further recent study to determine the
extent to which ethyl-EPA might reduce the rate of
progress of cerebral atrophy. High-resolution cerebral
magnetic resonance imaging scans were acquired at
baseline, six months and one year in up to 34 patients
with stage I or II Huntington’s disease who took part in
the trial of ethyl-EPA. For each subject and each pair of
structural images, the two-timepoint brain volume
change was calculated in a double-blind manner.
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